Prostate Cancer Drug Futures

Date: October 22, 2010
Price:
US$ 2,615.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P3DCC66A6CFEN
Leaflet:

Download PDF Leaflet

Prostate Cancer Drug Futures
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Prostate Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document. All for one cost-effective annual price of £1,495/US$2,615/€1,865

24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license period
Related news
Espicom’s research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.

The prostate cancer (PC) market is on the verge of considerable change....
....with the imminent arrival of new targeted therapies that will prolong patient survival. PC is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PC and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PC survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries

The PC market was estimated to be worth US$5.2 billion in 2008; it is one of the larger segments of the oncology market, alongside breast, non-small cell lung and colorectal cancers. The market is currently driven by the use of hormonal therapies, which are prescribed mainly for advanced hormone-dependent PC. However, the market dynamics will change considerably over the next six years as patents expire and generic competition intensifies. Research into new therapies is extremely active and new agents with novel modes of action are being evaluated.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Prostate Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...
  • Track the drug’s progress and stay abreast of developments
  • Understand the drug’s novelty and mode of action
  • Evaluate the strength of the company developing/producing the drug
  • Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
  • Know the launch timeframe for new products or indications
  • Be aware of promising mid-stage development candidates
  • Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
  • Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
  • Novelty/rationale for mechanism of action
  • Current status
  • Proof of concept/clinical data
  • Development risks
  • Company expertise
  • Competition within the market-place
  • Sales forecast (for key late-stage and launched products)
  • Competitor ratio analysis score
  • Clinical trial results
OVER 45 PROSTATE DRUGS INCLUDE:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved
  • Bicalutamide
  • Cabazitaxel
  • Degarelix
  • Docetaxel
  • Goserelin
  • Leuprorelin
  • Mitoxantrone
  • Paclitaxel
  • Sipuleucel-T
Filed
  • Dutasteride
Phase III
  • Abiraterone acetate
  • Aflibercept
  • Dasatinib
  • Ipilimumab
  • Radium-223
  • ZD4054
Phase II
  • AT-101
  • Bortezomib
  • Cixutumumab
  • E75 GM-CSF adjuvant vaccine
  • Enzastaurin
  • Figitumumab
  • Ixabepilone
  • OGX-011
  • OnyVax-P
  • PROSTVAC
  • Ramucirumab
  • Sagopilone
  • Vadimezan
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom’s Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom’s tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom’s leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

For further information on the products covered, discounts, distribution or a demonstration, please click on the link for Mark Hamson.

SECTORS COVERED IN THE CANCER DRUG FUTURE SERVICE
  • Breast
  • Lung
  • Colorectal
  • Renal Cell Carcinoma
  • Prostate
  • Blood (coming soon)
OVERVIEW

PHASE I

AE37


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

ASP0265

Current Status

SAR109659

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

PHASE I/II

BORTEZOMIB


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

PHASE II

AT-101


Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

CIXUTUMUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

CUSTIRSEN SODIUM

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis28

DEGARELIX

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast

DOVITINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise

E75 GM-CSF ADJUVANT VACCINE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast

ENZASTAURIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

ERBULIN

Clinical Trial Results

FIGITUMUMAB

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

IXABEPILONE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

LY2181308

Mode of Action
Current Status
Proof of Concept/Clinical Data

ONYVAX-P

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PROSTVAC

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

RAMUCIRUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

SAGOPILONE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

TASQ

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

VADIMEZAN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast
Source: Espicom
Clinical Trial Results

PHASE III

ABIRATERONE ACETATE


Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

AFLIBERCEPT

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

DASATINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

DUTASTERIDE

Mode of Action
Sales
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

GVAX

Clinical Trial Results
Monotherapy
Combination with Ipilimumab

IPILIMUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

MDV3100

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PICOPLATIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Competitor Ratio Analysis

RADIUM-223

Mode of Action
Current Status
Clinical Trial Results

SUNITINIB MALATE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

TOREMIFENE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

TRABECTEDIN

Mode of Action
Current Status
Further Development
Clinical Trial Results

ZD4054

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

FILED

CABAZITAXEL


Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

SATRAPLATIN

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competitor Ratio Analysis133
Forecast

APPROVED

BICALUTAMIDE


Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Generic Competition
Competitor Ratio Analysis
Forecast

CYPROTERONE ACETATE

Mode of Action
Current Status

DOCETAXEL

Mode of Action
Sales
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

GOSERELIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast

LEUPRORELIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast

MITOXANTRONE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Clinical Trial Results

SIPULEUCEL-T

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

WITHDRAWN

BEVACIZUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis189
Forecast
Clinical Trial Results

SARACATINIB

Mode of Action

METHODOLOGY
Skip to top


Prostate Cancer Drug Discoveries: What the Future Holds US$ 2,265.00 Nov, 2009 · 160 pages
Breast Cancer Drug Futures US$ 2,615.00 Oct, 2010
Lung Cancer Drug Futures US$ 2,615.00 Oct, 2010
Colorectal Cancer Drug Futures US$ 2,615.00 Oct, 2010

Ask Your Question

Prostate Cancer Drug Futures
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: